Insights

A 3D rendering of multiple blue cells floating in a microscopic environment, depicting detailed cellular structures.

Part 2: The Invention of PCR

2026.01.06
The author first heard the term “PCR” in the early 1980s while undergoing training on a DNA synthesizer in the sub… 黒澤伸行

青色の細胞が多数浮遊している様子を表した3Dイメージ画像。顕微鏡観察をモデル化した細胞構造のレンダリング

Part 1 The “Analyzing Life’s Mysteries” Project Was Born from Analytical Instrument Development

2025.11.17
This series is based on a manuscript I had the honor of writing for the Journal of the Society for Biotechnology, Japan, “Continuation of the Fundamentals of Biotechnology Lecture Series/Miscel… 黒澤伸行

腫瘍微小環境における複数の細胞集団（B細胞、CTL、Tヘルパー、M1/M2マクロファージなど）の空間分布と、距離および密度の比較解析を示す可視化図

The Path to Clinical Relevance: Moving from Spatial Transcriptomics to Protein Profiling

2025.11.20
Spatial biology is a rapidly evolving field that leverages imaging technologies to advance human health. This domain encompasses a broad range of research activities, from whole-transcriptome analysis to clinically meaningfu… 黒澤伸行

Introductory Knowledge of Intellectual Property in Life Sciences – The Essential Relationship Between Medicines and Patents

Vol. 9: Wait what? Generic Drugs can be Denied Approval?!—What is Patent Linkage?－

2026.03.01
Did the title “Generic Drugs Can Be Denied Approval?!” surprise you?This topic is connected to the so-called “patent linkage” system that I briefly mentioned inVol. 5,“Do The… 黒澤伸行

Vol. 8: Monetization from Litigation to Licensing: The Opdivo vs. Keytruda Patent War

2026.01.30
Last time, we discussed Patent Invalidation Trials as the most powerful counteraction when accused of patent infringement. Filing a lawsuit against acts that infringe a patent right, and the other party respo… 黒澤伸行

Vol. 7: Wait what? You can squash a patent? – How to Defeat Patents That Block Advances in Life Science Business-

2025.11.30
Last time, we discussed patent litigation. The most powerful counteraction when accused of patent infringement is to “squash the patent” — that is, to invalidate it. If the patent can be invalidated, the rights that … 黒澤伸行

Vol. 6: Sued for Patent Infringement? – Here’s How the Litigation would Unfold –

2025.11.01
Unlike the United States—a country known for its litigious culture – Japan sees relatively few patent lawsuits. However, the situation is somewhat different in the life sciences sector. In May of this year, a high-profile p… 黒澤伸行

Vol. 5: Do they really creep in? – Development schedules of Generics and Biosimilars

2025.09.30
This time, we are going to talk about generic drugs and biosimilars. These days in Japan we don't hear the word "zoro", but up until about 20 years ago, generic drugs were commonly referred to as "zoro." The word “zoro” stems … 黒澤伸行

Vol. 4: What do you mean “patents can be extended”? – Patent Term Extension: A special system for pharma–

2025.09.01
Last time, we discussed how to obtain a patent, following the process from application to obtaining a patent. I touched on the length of a patent term at the end. Do you remember how long a patent term was? The answer is 20… 黒澤伸行

Vol. 3: Shall we talk about how to obtain a patent? – Process flow from patent application to obtaining a patent –

2025.07.31
So far, we’ve explored the medicine classification and patents (Vol. 1), and the reasons why Medicines and Patents are inseparable (Vol. 2). In this volume, the spotlight fa… 黒澤伸行

Part 2: The Invention of PCR

Part 1 The “Analyzing Life’s Mysteries” Project Was Born from Analytical Instrument Development

The Path to Clinical Relevance: Moving from Spatial Transcriptomics to Protein Profiling

Vol. 9: Wait what? Generic Drugs can be Denied Approval?!—What is Patent Linkage?－

Vol. 8: Monetization from Litigation to Licensing: The Opdivo vs. Keytruda Patent War

Vol. 7: Wait what? You can squash a patent? – How to Defeat Patents That Block Advances in Life Science Business-

Vol. 6: Sued for Patent Infringement? – Here’s How the Litigation would Unfold –

Vol. 5: Do they really creep in? – Development schedules of Generics and Biosimilars

Vol. 4: What do you mean “patents can be extended”? – Patent Term Extension: A special system for pharma–

Vol. 3: Shall we talk about how to obtain a patent? – Process flow from patent application to obtaining a patent –

Popular articles/人気記事

Recent Posts/最近の投稿

Event Schedule

Insights

Part 2: The Invention of PCR

Part 1 The “Analyzing Life’s Mysteries” Project Was Born from Analytical Instrument Development

The Path to Clinical Relevance: Moving from Spatial Transcriptomics to Protein Profiling

Vol. 9: Wait what? Generic Drugs can be Denied Approval?!—What is Patent Linkage?－

Vol. 8: Monetization from Litigation to Licensing: The Opdivo vs. Keytruda Patent War

Vol. 7: Wait what? You can squash a patent? – How to Defeat Patents That Block Advances in Life Science Business-

Vol. 6: Sued for Patent Infringement? – Here’s How the Litigation would Unfold –

Vol. 5: Do they really creep in? – Development schedules of Generics and Biosimilars

Vol. 4: What do you mean “patents can be extended”? – Patent Term Extension: A special system for pharma–

Vol. 3: Shall we talk about how to obtain a patent? – Process flow from patent application to obtaining a patent –

Popular articles/人気記事

Recent Posts/最近の投稿

Event Schedule

Tag Cloud